Taysha Gene Therapies/TSHA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Taysha Gene Therapies

Taysha Gene Therapies Inc is a clinical-stage biotechnology company, which is focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. The Company’s lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder. The Company is evaluating TSHA-102 in the REVEALPhase I/II adolescent and adult clinical trial, which is a first-in-human, open-label, randomized, dose escalation and dose-expansion, multicenter study evaluating the safety and preliminary efficacy of TSHA-102 in female patients aged 12-years and older with Rett syndrome. It has acquired a worldwide right to a clinical-stage, intrathecally dosed AAV9 gene therapy program, TSHA-120, for the treatment of giant axonal neuropathy (GAN). It received orphan drug designation from the European Commission for TSHA-120 for the treatment of GAN.

Ticker

TSHA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Sean Nolan

Employees

52

Headquarters

Dallas, United States

TSHA Metrics

BasicAdvanced
$641M
Market cap
-
P/E ratio
-$1.19
EPS
0.47
Beta
-
Dividend rate
$641M
0.47251
$3.89
$0.50
2.4M
3.38
75.233
75.905
-92.70%
-606.69%
-146.13%
45.315
11.912
11.912
96.39%
56.85%

What the Analysts think about TSHA

Analyst Ratings

Majority rating from 10 analysts.
Buy

TSHA Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-705.88% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$3.4M
-5.56%
Net income
-$24M
-150.31%
Profit margin
-705.88%
-153.27%

TSHA Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 8.59%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.38
-$0.93
$0.92
-$0.10
-
Expected
-$0.31
-$0.17
-$0.11
-$0.11
-$0.17
Surprise
22.14%
438.51%
-936.36%
-8.59%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Taysha Gene Therapies stock?

Taysha Gene Therapies (TSHA) has a market cap of $641M as of June 15, 2024.

What is the P/E ratio for Taysha Gene Therapies stock?

The price to earnings (P/E) ratio for Taysha Gene Therapies (TSHA) stock is 0 as of June 15, 2024.

Does Taysha Gene Therapies stock pay dividends?

No, Taysha Gene Therapies (TSHA) stock does not pay dividends to its shareholders as of June 15, 2024.

When is the next Taysha Gene Therapies dividend payment date?

Taysha Gene Therapies (TSHA) stock does not pay dividends to its shareholders.

What is the beta indicator for Taysha Gene Therapies?

Taysha Gene Therapies (TSHA) has a beta rating of 0.47. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Taysha Gene Therapies stock price target?

The target price for Taysha Gene Therapies (TSHA) stock is $6.95, which is NaN% below the current price of $. This is an average based on projections from 10 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Taysha Gene Therapies stock

Buy or sell Taysha Gene Therapies stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing